Literature DB >> 14516936

BRCA1 in hormone-responsive cancers.

Eliot M Rosen1, Saijun Fan, Richard G Pestell, Itzhak D Goldberg.   

Abstract

Mutations of the breast cancer susceptibility gene BRCA1 are linked to hereditary early onset breast and breast-ovarian cancer syndromes. These mutations confer an increased risk for other hormone-dependent cancers, including those of the uterus, cervix and prostate. BRCA1 expression is decreased or absent in a significant proportion of sporadic breast and ovarian cancers, suggesting a wider role in these tumor types. Multiple functions for BRCA1 have been identified, including roles in DNA repair, cell-cycle progression and apoptosis. These functions are consistent with a tumor suppressor activity, but they do not explain why BRCA1 mutation carriers develop hormone-responsive cancer types. Recent studies indicate that BRCA1 interacts with and regulates the activity of estrogen receptor alpha (ER alpha) and the androgen receptor. Its expression is regulated by carcinogens and anticarcinogens that modulate ER alpha signaling, suggesting a molecular linkage between BRCA1 and hormone-responsive cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14516936     DOI: 10.1016/j.tem.2003.08.001

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  11 in total

1.  Quantitative proteomic identification of the BRCA1 ubiquitination substrates.

Authors:  Meihua Song; Kevin Hakala; Susan T Weintraub; Yuzuru Shiio
Journal:  J Proteome Res       Date:  2011-10-11       Impact factor: 4.466

Review 2.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

3.  The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.

Authors:  Yongxian Ma; Pragati Katiyar; Laundette P Jones; Saijun Fan; Yiyu Zhang; Priscilla A Furth; Eliot M Rosen
Journal:  Mol Endocrinol       Date:  2005-08-18

4.  Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.

Authors:  Hagit Schayek; Kathy Haugk; Shihua Sun; Lawrence D True; Stephen R Plymate; Haim Werner
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

5.  Liver X receptor ligands suppress ubiquitination and degradation of LXRalpha by displacing BARD1/BRCA1.

Authors:  Kang Ho Kim; Jeong Min Yoon; A Hyun Choi; Woo Sik Kim; Gha Young Lee; Jae Bum Kim
Journal:  Mol Endocrinol       Date:  2009-01-22

6.  Detoxification: a novel function of BRCA1 in tumor suppression?

Authors:  Hyo Jin Kang; Young Bin Hong; Hee Jeong Kim; Olga C Rodriguez; Raghu G Nath; Elena M Tilli; Christopher Albanese; Fung-Lung Chung; Sang Hoon Kwon; Insoo Bae
Journal:  Toxicol Sci       Date:  2011-04-19       Impact factor: 4.849

Review 7.  A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Authors:  Fatemeh Karami; Parvin Mehdipour
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

Review 8.  BRCA1: An Endocrine and Metabolic Regulator.

Authors:  Haim Werner
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-31       Impact factor: 5.555

9.  The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.

Authors:  Xue Lin; Bahman Afsari; Luigi Marchionni; Leslie Cope; Giovanni Parmigiani; Daniel Naiman; Donald Geman
Journal:  BMC Bioinformatics       Date:  2009-08-20       Impact factor: 3.169

Review 10.  A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.

Authors:  Adisorn Ratanaphan
Journal:  Int J Mol Sci       Date:  2012-11-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.